Corporate
Sarepta's ELEVIDYS Shows 70%+ Disease Slowing at 3 Years—Stock Surges 13% on Redemption Data
Jan 26
You're signed outSign in or to get full access.
ST
Sarepta Therapeutics (SRPT)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Q4 2023
View earnings summary and analysis
Research analysts covering Sarepta Therapeutics.